Hua Medicine

02552

Company Profile

  • Business description

    Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from PRC.

  • Contact

    Lane 36, Xuelin Road
    Hua Medicine, Building 2
    Pudong New Area
    Shanghai201203
    CHN

    T: +86 2138101800

    https://www.huamedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    168

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,963.5029.200.33%
CAC 407,833.461.12-0.01%
DAX 4024,133.2684.24-0.35%
Dow JONES (US)44,901.92208.010.47%
FTSE 1009,096.1724.14-0.26%
HKSE25,562.13173.780.68%
NASDAQ21,108.3250.360.24%
Nikkei 22540,998.27457.96-1.10%
NZX 50 Index12,910.7457.280.45%
S&P 5006,388.640.000.00%
S&P/ASX 2008,697.7030.800.36%
SSE Composite Index3,597.944.280.12%

Market Movers